Lovastatin discovery in Fragile X mice leads FRAXA to fund Clinical Trials

Available medication Lovastatin corrects excess protein synthesis in Fragile X mice At the opening dinner of the 2011 FRAXA Investigators Meeting in Southbridge, MA,  Dr. Emily Osterweil was awarded the FRAXA Pioneer Award  for work demonstrating that Lovastatin could treat Fragile X.  Dr. Osterweil conducted her experiments in the MIT laboratory of Dr. Mark Bear; she has since established her own laboratory at the University of Edinburgh. The team discovered that lovastatin, a drug widely prescribed for high cholesterol, can correct excess hippocampal protein synthesis in the mouse model of FXS and can prevent epileptogenesis. The work is published in the prestigious neuroscience journal Neuron: Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome. One implication of the mGluR theory of Fragile X is that there are exaggerated consequences of activation of signaling pathways which link metabotropic glutamate receptors (mGluRs) to the cellular machinery of neurons. It